Phase 2 Pancreatic Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People aged 18 to 75 years old, both male and female, who are willing to give written consent to participate.
• People who have been diagnosed with pancreatic cancer that cannot be removed by surgery and has either spread to nearby areas or to other parts of the body, confirmed by tissue or cell testing.
• People whose cancer can be measured using standard imaging criteria (known as RECIST 1.1).
• People who have not yet received any systemic (whole-body) treatment for their pancreatic cancer.
• People with a general physical functioning score of 0–2 on a standard scale used by doctors to assess daily activity levels (confirm with trial site).
• People whose doctors estimate they have a life expectancy of at least 3 months.
• People with adequate bone marrow and blood clotting function, as assessed by the trial site.

Who may not be able to join:

• People with a known allergy or sensitivity to any ingredient in the study drug.
• People who have previously been treated with drugs that specifically target a protein called CSF-1 or its receptor CSF-1R.
• People who have a mutation in the BRCA1 or BRCA2 genes.
• People who have had another type of cancer within the past 5 years.
• People who would need to use other cancer treatments during the trial, such as chemotherapy, targeted therapy, hormone therapy, immunotherapy, or radiotherapy (except radiotherapy used only to relieve local symptoms).
• People who have a condition that significantly affects the body's ability to absorb oral (swallowed) medication.
• People who have had surgery within 4 weeks before starting the trial, or whose previous surgical wounds have not fully healed, are infected, or have reopened.
• People who have been receiving regular steroid treatment or any other medication that suppresses the immune system within the 2 weeks before starting the trial.
• People who have taken certain medications known to strongly affect how the body processes a liver enzyme called CYP3A4 within 14 days before joining (confirm with trial site).
• People who already have nerve damage in their hands or feet rated above a mild level (Grade 1) before joining.
• People diagnosed with an immune deficiency condition or a lung disease called interstitial lung disease.
• People who have received a vaccine within 4 weeks before starting the trial.
• People who have taken part in another drug clinical trial within 4 weeks before starting this trial.
• People who have active cancer spread to the brain or central nervous system.
• People with significant heart problems or heart disease.
• People with known active liver or bile duct disease, or other conditions likely to affect liver test results during the study.
• People with known active infections from certain viruses, bacteria, or parasites (confirm with trial site for specific details).
• People with severe or uncontrolled fluid build-up in the abdomen or around the lungs.
• People who are pregnant or currently breastfeeding.
• People with any other significant health condition that the trial doctor believes would make participation unsuitable.

Important: Always verify eligibility with the trial site directly before applying.